Efficacy and Safety of Ushaq Capsule as Adjunctive Therapy in Patients With Lumbar Radiculopathy: A Double‐Blind, Randomized, Placebo‐Controlled Clinical Trial at Imam Khomeini Hospital, Tehran, Iran
- 26 October 2026
- journal article
- Published by Wiley in Musculoskeletal Care
- Vol. 24 (4)
Abstract
Background: Sciatica and lumbar radicular pain are prevalent symptoms affecting a large proportion of people worldwide. Many patients seek complementary and alternative medicine for pain relief. This study aimed to evaluate the efficacy and safety of Ushaq capsule, a herbal formulation from Traditional Persian Medicine, on pain intensity and disability in patients with lumbar radiculopathy. Methods: This randomized, double‐blind, placebo‐controlled clinical trial included 68 patients randomly assigned to intervention or placebo groups. All participants were allowed to use diclofenac 50 mg (up to three tablets daily) as rescue medication for breakthrough pain. Participants in the intervention group received 3 Ushaq capsules daily for 6 weeks, while the placebo group received identical microcrystalline cellulose capsules. Pain intensity and disability were assessed using the Visual Analogue Scale (VAS) and Roland Morris Disability Questionnaire (RMDQ). The primary endpoint was the change in VAS score from baseline to week 6. Safety was evaluated through clinical adverse event monitoring and laboratory tests. Results: No significant baseline differences were observed between the groups ( p > 0.05). The mean VAS score was significantly lower in the Ushaq group from the second week onward ( p = 0.019) and remained significant until the end of the study ( p = 0.003). The RMDQ score decreased significantly in both groups, but the reduction in the Ushaq group was not significantly greater than that in the placebo group ( p = 0.218). No serious adverse events were reported; only mild, transient gastrointestinal discomfort occurred ( Ushaq : 6.5%, placebo: 4.3%). Conclusions: Ushaq capsules as adjunctive therapy with diclofenac as rescue medication showed greater pain reduction compared to placebo with a favourable safety profile. Larger, longer‐term trials with active comparators are needed to confirm these preliminary findings. Trail Registration: The research was registered with the Iranian Registry of Clinical Trials (IRCT) and received registration number IRCT20200418047124N1Keywords
Funding Information
- Tehran University of Medical Sciences and Health Services
This publication has 25 references indexed in Scilit:
- Medication recommendations for treatment of lumbosacral radiculopathy: A systematic review of clinical practice guidelinesPM&R, 2024
- The effect of a topical formulation from Lawsonia inermis L. (henna) on pain intensity in patients with chronic sciatica: A randomized double-blind clinical trialJournal of Ethnopharmacology, 2023
- Epidural corticosteroid injections for lumbosacral radicular painCochrane Database of Systematic Reviews, 2020
- Non-steroidal anti-inflammatory drugs for sciaticaCochrane Database of Systematic Reviews, 2016
- The Short-Term Effect of Integrated Complementary and Alternative Medicine Treatment in Inpatients Diagnosed with Lumbar Intervertebral Disc Herniation: A Prospective Observational StudyThe Journal of Alternative and Complementary Medicine, 2016
- An evidence-based clinical guideline for the diagnosis and treatment of lumbar disc herniation with radiculopathyThe Spine Journal, 2014
- Role of cytokines in intervertebral disc degeneration: pain and disc contentNature Reviews Rheumatology, 2013
- Incidence and Epidemiology of Cervical Radiculopathy in the United States MilitaryJournal of Spinal Disorders & Techniques, 2012
- Recent advancements in the treatment of lumbar radicular painCurrent Opinion in Anaesthesiology, 2008
- The Oswestry Disability Index, the Roland-Morris Disability Questionnaire, and the Quebec Back Pain Disability Scale: Translation and Validation Studies of the Iranian VersionsSpine, 2006